These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 32313032)

  • 1. Steroid hormone secretion after stimulation of mineralocorticoid and NMDA receptors and cardiovascular risk in patients with depression.
    Nowacki J; Wingenfeld K; Kaczmarczyk M; Chae WR; Salchow P; Abu-Tir I; Piber D; Hellmann-Regen J; Otte C
    Transl Psychiatry; 2020 Apr; 10(1):109. PubMed ID: 32313032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive and emotional empathy after stimulation of brain mineralocorticoid and NMDA receptors in patients with major depression and healthy controls.
    Nowacki J; Wingenfeld K; Kaczmarczyk M; Chae WR; Abu-Tir I; Deuter CE; Piber D; Hellmann-Regen J; Otte C
    Neuropsychopharmacology; 2020 Dec; 45(13):2155-2161. PubMed ID: 32722659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective attention to emotional stimuli and emotion recognition in patients with major depression: The role of mineralocorticoid and glutamatergic NMDA receptors.
    Nowacki J; Wingenfeld K; Kaczmarczyk M; Chae WR; Salchow P; Deuter CE; Piber D; Otte C
    J Psychopharmacol; 2021 Aug; 35(8):1017-1023. PubMed ID: 33908312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No influence of mineralocorticoid and glutamatergic NMDA receptor stimulation on spatial learning and memory in individuals with major depression.
    Kaczmarczyk M; Wingenfeld K; Nowacki J; Chae WR; Deuter CE; Piber D; Otte C
    J Psychiatr Res; 2022 Aug; 152():97-103. PubMed ID: 35717867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mineralocorticoid receptor function in depressed patients and healthy individuals.
    Hinkelmann K; Hellmann-Regen J; Wingenfeld K; Kuehl LK; Mews M; Fleischer J; Heuser I; Otte C
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Nov; 71():183-8. PubMed ID: 27519144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mineralocorticoid receptor stimulation improves cognitive function and decreases cortisol secretion in depressed patients and healthy individuals.
    Otte C; Wingenfeld K; Kuehl LK; Kaczmarczyk M; Richter S; Quante A; Regen F; Bajbouj M; Zimmermann-Viehoff F; Wiedemann K; Hinkelmann K
    Neuropsychopharmacology; 2015 Jan; 40(2):386-93. PubMed ID: 25035081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased glucocorticoid metabolism in diabetic kidney disease.
    Ackermann D; Vogt B; Bochud M; Burnier M; Martin PY; Paccaud F; Ehret G; Guessous I; Ponte B; Pruijm M; Pechère-Bertschi A; Jamin H; Klossner R; Dick B; Mohaupt MG; Gennari-Moser C
    PLoS One; 2022; 17(6):e0269920. PubMed ID: 35749380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. D-cycloserine normalizes long-term motor plasticity after transcranial magnetic intermittent theta-burst stimulation in major depressive disorder.
    Cole J; Selby B; Ismail Z; McGirr A
    Clin Neurophysiol; 2021 Aug; 132(8):1770-1776. PubMed ID: 34130243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mineralocorticoid receptor function in major depression.
    Young EA; Lopez JF; Murphy-Weinberg V; Watson SJ; Akil H
    Arch Gen Psychiatry; 2003 Jan; 60(1):24-8. PubMed ID: 12511169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased hydrocortisone sensitivity of T cell function in multiple sclerosis-associated major depression.
    Fischer A; Otte C; Krieger T; Nicholls RA; Krüger S; Ziegler KJ; Schulz KH; Heesen C; Gold SM
    Psychoneuroendocrinology; 2012 Oct; 37(10):1712-8. PubMed ID: 22455832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pro-inflammatory Monocyte Phenotype and Cell-Specific Steroid Signaling Alterations in Unmedicated Patients With Major Depressive Disorder.
    Hasselmann H; Gamradt S; Taenzer A; Nowacki J; Zain R; Patas K; Ramien C; Paul F; Wingenfeld K; Piber D; Gold SM; Otte C
    Front Immunol; 2018; 9():2693. PubMed ID: 30532752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Target-based biomarker selection - Mineralocorticoid receptor-related biomarkers and treatment outcome in major depression.
    Büttner M; Jezova D; Greene B; Konrad C; Kircher T; Murck H
    J Psychiatr Res; 2015; 66-67():24-37. PubMed ID: 25959615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does fludrocortisone influence autobiographical memory retrieval? A study in patients with major depression, patients with borderline personality disorder and healthy controls.
    Fleischer J; Wingenfeld K; Kuehl LK; Hinkelmann K; Roepke S; Otte C
    Stress; 2015; 18(6):718-22. PubMed ID: 26457343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study.
    Otte C; Hinkelmann K; Moritz S; Yassouridis A; Jahn H; Wiedemann K; Kellner M
    J Psychiatr Res; 2010 Apr; 44(6):339-46. PubMed ID: 19909979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mineralocorticoid receptor agonist, fludrocortisone, differentially inhibits pituitary-adrenal activity in humans with psychotic major depression.
    Lembke A; Gomez R; Tenakoon L; Keller J; Cohen G; Williams GH; Kraemer FB; Schatzberg AF
    Psychoneuroendocrinology; 2013 Jan; 38(1):115-21. PubMed ID: 22727477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salivary alpha-amylase and cortisol responsiveness following electrical stimulation stress in major depressive disorder patients.
    Tanaka Y; Ishitobi Y; Maruyama Y; Kawano A; Ando T; Okamoto S; Kanehisa M; Higuma H; Ninomiya T; Tsuru J; Hanada H; Kodama K; Isogawa K; Akiyoshi J
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Mar; 36(2):220-4. PubMed ID: 22063648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mineralocorticoid receptor blockade by canrenoate increases both spontaneous and stimulated adrenal function in humans.
    Arvat E; Maccagno B; Giordano R; Pellegrino M; Broglio F; Gianotti L; Maccario M; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3176-81. PubMed ID: 11443185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morning salivary dehydroepiandrosterone (DHEA) qualifies as the only neuroendocrine biomarker separating depressed patients with and without prior history of depression: An HPA axis challenge study.
    Agorastos A; Heinig A; Sommer A; Wiedemann K; Demiralay C
    J Psychiatr Res; 2023 May; 161():449-454. PubMed ID: 37059029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mineralocorticoid receptor agonist, fludrocortisone, inhibits pituitary-adrenal activity in humans after pre-treatment with metyrapone.
    Otte C; Jahn H; Yassouridis A; Arlt J; Stober N; Maass P; Wiedemann K; Kellner M
    Life Sci; 2003 Aug; 73(14):1835-45. PubMed ID: 12888122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cortisol/DHEA ratio and hippocampal volume: A pilot study in major depression and healthy controls.
    Jin RO; Mason S; Mellon SH; Epel ES; Reus VI; Mahan L; Rosser RL; Hough CM; Burke HM; Mueller SG; Wolkowitz OM
    Psychoneuroendocrinology; 2016 Oct; 72():139-46. PubMed ID: 27428086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.